NASDAQ:CDXC ChromaDex - CDXC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ChromaDex Co. Please log in to your account or sign up in order to add this asset to your watchlist. $2.05 -0.04 (-1.91%) (As of 02/3/2023 12:00 PM ET) Add Compare Share Share Today's Range$1.99▼$2.0950-Day Range$1.46▼$2.1952-Week Range$1.15▼$3.16Volume214,122 shsAverage Volume254,310 shsMarket Capitalization$152.66 millionP/E RatioN/ADividend YieldN/APrice Target$5.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ChromaDex MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside170.0% Upside$5.40 Price TargetShort InterestBearish4.66% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.45Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.24) to ($0.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector386th out of 1,029 stocksMedicinals & Botanicals Industry2nd out of 15 stocks 3.3 Analyst's Opinion Consensus RatingChromaDex has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.40, ChromaDex has a forecasted upside of 170.0% from its current price of $2.00.Amount of Analyst CoverageChromaDex has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.66% of the float of ChromaDex has been sold short.Short Interest Ratio / Days to CoverChromaDex has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in ChromaDex has recently increased by 2.19%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldChromaDex does not currently pay a dividend.Dividend GrowthChromaDex does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChromaDex has received a 68.93% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Dietary supplements" products. See details.Environmental SustainabilityThe Environmental Impact score for ChromaDex is -0.95. Previous Next 2.5 News and Social Media Coverage News SentimentChromaDex has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for ChromaDex this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added ChromaDex to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ChromaDex insiders have not sold or bought any company stock.Percentage Held by Insiders11.80% of the stock of ChromaDex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.81% of the stock of ChromaDex is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ChromaDex are expected to grow in the coming year, from ($0.24) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ChromaDex is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ChromaDex is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChromaDex has a P/B Ratio of 4.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ChromaDex (NASDAQ:CDXC) StockChromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Read More Receive CDXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter. Email Address CDXC Stock News HeadlinesFebruary 3, 2023 | americanbankingnews.comOppenheimer Weighs in on ChromaDex Co.'s FY2022 Earnings (NASDAQ:CDXC)February 2, 2023 | americanbankingnews.comChromaDex (NASDAQ:CDXC) Receives Buy Rating from HC WainwrightFebruary 3, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 31, 2023 | finance.yahoo.comChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) PatientsJanuary 17, 2023 | finance.yahoo.comChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial BiogenesisJanuary 15, 2023 | finance.yahoo.comStrong week for ChromaDex (NASDAQ:CDXC) shareholders doesn't alleviate pain of five-year lossJanuary 5, 2023 | finance.yahoo.comChromaDex Named Brianna Gerber Chief Financial OfficerDecember 27, 2022 | finance.yahoo.comChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative BiomarkersFebruary 3, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 19, 2022 | finance.yahoo.comDown 9.6% in 4 Weeks, Here's Why ChromaDex (CDXC) Looks Ripe for a TurnaroundDecember 16, 2022 | finance.yahoo.comHere's Why ChromaDex (CDXC) is Poised for a Turnaround After Losing 7.5% in 4 WeeksNovember 11, 2022 | finance.yahoo.comChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United StatesOctober 26, 2022 | finance.yahoo.comChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022October 24, 2022 | finance.yahoo.comChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet AwardsOctober 20, 2022 | money.usnews.comChromadex CorpOctober 15, 2022 | nasdaq.comShareholders in ChromaDex (NASDAQ:CDXC) are in the red if they invested a year ago - NasdaqOctober 11, 2022 | businesswire.comChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment - Business WireOctober 11, 2022 | finance.yahoo.comChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million InvestmentOctober 6, 2022 | finance.yahoo.comTrade Alert: Hoi Shuen Chau At ChromaDex Corporation (NASDAQ:CDXC), Has Just Spent US$1.2m Buying 14% More SharesOctober 5, 2022 | benzinga.comChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock - ChromaDex (NASDAQ:CDXC) - BenzingaOctober 4, 2022 | nasdaq.comTuesday 10/4 Insider Buying Report: CDXC, KTTA - NasdaqOctober 4, 2022 | benzinga.com$1.2 Million Bet On ChromaDex? Check Out These 4 Penny Stocks Insiders Are Buying - ChromaDex (NASDAQ:CDX - BenzingaOctober 4, 2022 | businesswire.comChromaDex Shares Promising Findings from Clinical Study Showcasing the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction - Business WireOctober 4, 2022 | finance.yahoo.comChromaDex Shares Promising Findings from Clinical Study Showcasing the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection FractionOctober 3, 2022 | seekingalpha.comChromaDex forms JV in Asia for Tru Niagen; plans to raise $3.1M via stock sale - Seeking AlphaOctober 3, 2022 | finance.yahoo.comChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common StockSeptember 19, 2022 | businesswire.comSinopharm Xingsha to Introduce ChromaDex's Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE) - Business WireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CDXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter. Email Address CDXC Company Calendar Last Earnings11/02/2021Today2/03/2023Next Earnings (Estimated)3/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CDXC CUSIPN/A CIK1386570 Webwww.chromadex.com Phone(310) 388-6706Fax949-419-0294Employees115Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.40 High Stock Price Forecast$7.00 Low Stock Price Forecast$2.10 Forecasted Upside/Downside+163.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,130,000.00 Net Margins-29.71% Pretax Margin-29.71% Return on Equity-90.73% Return on Assets-44.42% Debt Debt-to-Equity RatioN/A Current Ratio2.27 Quick Ratio1.33 Sales & Book Value Annual Sales$67.45 million Price / Sales2.26 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book4.46Miscellaneous Outstanding Shares74,470,000Free Float65,682,000Market Cap$152.66 million OptionableOptionable Beta1.77 Key ExecutivesRobert N. FriedChief Executive Officer & DirectorBrianna GerberChief Financial OfficerRyan DellingerDirector-Scientific AffairsFadi KaramChief Marketing OfficerTrent CraneRegional Vice President-SalesKey CompetitorsMind Medicine (MindMed)NASDAQ:MNMDMediWoundNASDAQ:MDWDHEXONYSE:HEXOBright GreenNASDAQ:BGXXValensNASDAQ:VLNSView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 2,100 shares on 2/2/2023Ownership: 0.000%Cowen Prime Advisors LLCBought 71,157 shares on 2/1/2023Ownership: 0.101%International Assets Investment Management LLCBought 20,000 shares on 1/30/2023Ownership: 0.027%BlackRock Inc.Sold 5,843 shares on 11/15/2022Ownership: 1.320%Two Sigma Advisers LPSold 10,300 shares on 11/15/2022Ownership: 0.056%View All Insider TransactionsView All Institutional Transactions CDXC Stock - Frequently Asked Questions Should I buy or sell ChromaDex stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDXC shares. View CDXC analyst ratings or view top-rated stocks. What is ChromaDex's stock price forecast for 2023? 4 brokers have issued 12 month price objectives for ChromaDex's stock. Their CDXC share price forecasts range from $2.10 to $7.00. On average, they expect the company's share price to reach $5.40 in the next twelve months. This suggests a possible upside of 158.4% from the stock's current price. View analysts price targets for CDXC or view top-rated stocks among Wall Street analysts. How have CDXC shares performed in 2023? ChromaDex's stock was trading at $1.68 on January 1st, 2023. Since then, CDXC shares have increased by 24.4% and is now trading at $2.09. View the best growth stocks for 2023 here. When is ChromaDex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023. View our CDXC earnings forecast. How were ChromaDex's earnings last quarter? ChromaDex Co. (NASDAQ:CDXC) released its earnings results on Tuesday, November, 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.04. The company earned $17.31 million during the quarter, compared to analyst estimates of $17.18 million. ChromaDex had a negative net margin of 29.71% and a negative trailing twelve-month return on equity of 90.73%. During the same quarter in the prior year, the company posted ($0.07) EPS. What is Robert Fried's approval rating as ChromaDex's CEO? 13 employees have rated ChromaDex Chief Executive Officer Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among the company's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 46.0% of employees surveyed would recommend working at ChromaDex to a friend. What other stocks do shareholders of ChromaDex own? Based on aggregate information from My MarketBeat watchlists, some companies that other ChromaDex investors own include Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), ADMA Biologics (ADMA), Athersys (ATHX), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Tilray (TLRY), Dynavax Technologies (DVAX), Glu Mobile (GLUU) and Great Panther Mining (GPL). What is ChromaDex's stock symbol? ChromaDex trades on the NASDAQ under the ticker symbol "CDXC." Who are ChromaDex's major shareholders? ChromaDex's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cowen Prime Advisors LLC (0.10%), International Assets Investment Management LLC (0.03%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Frank L Jaksch Jr, Hoi Shuen Solina Holly Chau, Kevin M Farr, Robert N Fried and Stephen A Block. View institutional ownership trends. How do I buy shares of ChromaDex? Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ChromaDex's stock price today? One share of CDXC stock can currently be purchased for approximately $2.09. How much money does ChromaDex make? ChromaDex (NASDAQ:CDXC) has a market capitalization of $155.64 million and generates $67.45 million in revenue each year. The company earns $-27,130,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. How many employees does ChromaDex have? The company employs 115 workers across the globe. How can I contact ChromaDex? ChromaDex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The official website for the company is www.chromadex.com. The company can be reached via phone at (310) 388-6706, via email at investorrelations@chromadex.com, or via fax at 949-419-0294. This page (NASDAQ:CDXC) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.